abrdn Life Sciences Investors (NYSE:HQL) Short Interest Update

abrdn Life Sciences Investors (NYSE:HQL) saw a large decrease in short interest in June. As of June 30th, there was short interest totaling 14,265 shares, a decrease of 60.1% from the June 15th total of 35,781 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average trading volume of 150,344 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Trading of abrdn Life Sciences Investors

Institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada lifted its stake in shares of abrdn Life Sciences Investors by 53.3% in the first quarter. Royal Bank of Canada now owns 73,475 shares of the company’s stock worth $934,000 after buying an additional 25,542 shares during the last quarter. NewEdge Advisors LLC grew its stake in abrdn Life Sciences Investors by 43.1% in the 1st quarter. NewEdge Advisors LLC now owns 32,500 shares of the company’s stock valued at $412,000 after buying an additional 9,785 shares during the last quarter. First Trust Advisors LP grew its stake in abrdn Life Sciences Investors by 112.2% in the 2nd quarter. First Trust Advisors LP now owns 35,321 shares of the company’s stock valued at $452,000 after buying an additional 18,674 shares during the last quarter. Raymond James Financial Inc. raised its holdings in abrdn Life Sciences Investors by 20.3% in the 2nd quarter. Raymond James Financial Inc. now owns 375,960 shares of the company’s stock worth $4,816,000 after acquiring an additional 63,429 shares during the period. Finally, Clough Capital Partners L P bought a new position in abrdn Life Sciences Investors in the 2nd quarter worth $318,000. 32.21% of the stock is currently owned by institutional investors and hedge funds.

abrdn Life Sciences Investors Price Performance

Shares of NYSE HQL opened at $20.34 on Monday. The business’s 50-day simple moving average is $18.19 and its 200-day simple moving average is $17.35. abrdn Life Sciences Investors has a 52 week low of $12.87 and a 52 week high of $21.32.

abrdn Life Sciences Investors Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Thursday, May 21st were issued a dividend of $0.56 per share. This represents a $2.24 annualized dividend and a yield of 11.0%. The ex-dividend date was Thursday, May 21st.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.